Ryutaro Asano

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/859168/publications.pdf

Version: 2024-02-01

63	1,065	361413	477307
papers	citations	20	29
		h-index	g-index

65	65	65	856
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Development of a POCT type insulin sensor employing anti-insulin single chain variable fragment based on faradaic electrochemical impedance spectroscopy under single frequency measurement. Biosensors and Bioelectronics, 2022, 200, 113901.	10.1	13
2	Transient potentiometry based d-serine sensor using engineered d-amino acid oxidase showing quasi-direct electron transfer property. Biosensors and Bioelectronics, 2022, 200, 113927.	10.1	7
3	Light-induced production of isobutanol and 3-methyl-1-butanol by metabolically engineered cyanobacteria. Microbial Cell Factories, 2022, 21, 7.	4.0	10
4	Fabrication of Fragment Antibodyâ€“Enzyme Complex as a Sensing Element for Immunosensing. International Journal of Molecular Sciences, 2022, 23, 1335.	4.1	4
5	Development of a DNA aptamer that binds to the complementarity-determining region of therapeutic monoclonal antibody and affinity improvement induced by pH-change for sensitive detection. Biosensors and Bioelectronics, 2022, 203, 114027.	10.1	13
6	Development of Engineered Antibodies for Novel Electrochemical Immunosensors. Denki Kagaku, 2022, 90, 69-69.	0.0	0
7	Strategies to simplify operation procedures for applying labeled antibody-based immunosensors to point-of-care testing. Analytical Biochemistry, 2022, 654, 114806.	2.4	4
8	Mechanism of action of a T cell-dependent bispecific antibody as a breakthrough immunotherapy against refractory colorectal cancer with an oncogenic mutation. Cancer Immunology, Immunotherapy, 2021, 70, 177-188.	4.2	13
9	Rapid and homogeneous electrochemical detection by fabricating a high affinity bispecific antibody-enzyme complex using two Catcher/Tag systems. Biosensors and Bioelectronics, 2021, 175, 112885.	10.1	12
10	Biosensors: Immunosensors. , 2021, , .		2
11	Anti-EGFR antibody 528 binds to domain III of EGFR at a site shifted from the cetuximab epitope. Scientific Reports, 2021, 11, 5790.	3.3	7
12	Strategic design and improvement of the internal electron transfer of heme b domain-fused glucose dehydrogenase for use in direct electron transfer-type glucose sensors. Biosensors and Bioelectronics, 2021, 176, 112911.	10.1	18
13	Rational design of direct electron transfer type l-lactate dehydrogenase for the development of multiplexed biosensor. Biosensors and Bioelectronics, 2021, 176, 112933.	10.1	40
14	Evaluation of intercellular cross-linking abilities correlated with cytotoxicities of bispecific antibodies with domain rearrangements using AFM force-sensing. Biosensors and Bioelectronics, 2021, 178, 113037.	10.1	3
15	Development of glycated peptide enzyme sensor based flow injection analysis system for haemoglobin A1c monitoring using quasi-direct electron transfer type engineered fructosyl peptide oxidase. Biosensors and Bioelectronics, 2021, 177, 112984.	10.1	12
16	Continuous electrochemical monitoring of L-glutamine using redox-probe-modified L-glutamine-binding protein based on intermittent pulse amperometry. Sensors and Actuators B: Chemical, 2021, 346, 130554.	7.8	7
17	Rapid, convenient, and highly sensitive detection of human hemoglobin in serum using a high-affinity bivalent antibodyâ€“enzyme complex. Talanta, 2021, 234, 122638.	5.5	10
18	T Cell Bispecific Antibodies: An Antibody-Based Delivery System for Inducing Antitumor Immunity. Pharmaceuticals, 2021, 14, 1172.	3.8	13

#	Article	IF	Citations
19	Rational engineering of Aerococcus viridans l-lactate oxidase for the mediator modification to achieve quasi-direct electron transfer type lactate sensor. Biosensors and Bioelectronics, 2020, 151, 111974.	10.1	43
20	Construction of a circularly connected VHH bispecific antibody (cyclobody) for the desirable positioning of antigen-binding sites. Biochemical and Biophysical Research Communications, 2020, 523, 72-77.	2.1	8
21	Functional Domain Order of an Anti-EGFR Ã— Anti-CD16 Bispecific Diabody Involving NK Cell Activation. International Journal of Molecular Sciences, 2020, 21, 8914.	4.1	7
22	Build-up functionalization of anti-EGFR Ã— anti-CD3 bispecific diabodies by integrating high-affinity mutants and functional molecular formats. Scientific Reports, 2020, 10, 4913.	3.3	4
23	Chemically Crosslinked Bispecific Antibodies for Cancer Therapy: Breaking from the Structural Restrictions of the Genetic Fusion Approach. International Journal of Molecular Sciences, 2020, 21, 711.	4.1	3
24	Application of an engineered chromatic acclimation sensor for red-light-regulated gene expression in cyanobacteria. Algal Research, 2019, 44, 101691.	4.6	9
25	Elucidation of the intra- and inter-molecular electron transfer pathways of glucoside 3-dehydrogenase. Bioelectrochemistry, 2018, 122, 115-122.	4.6	6
26	Affinity maturation of humanized anti-epidermal growth factor receptor antibody using a modified phage-based open sandwich selection method. Scientific Reports, 2018, 8, 5414.	3.3	4
27	Minimizing the effects of oxygen interference on l -lactate sensors by a single amino acid mutation in Aerococcus viridans l -lactate oxidase. Biosensors and Bioelectronics, 2018, 103, 163-170.	10.1	29
28	High-throughput cytotoxicity and antigen-binding assay for screening small bispecific antibodies without purification. Journal of Bioscience and Bioengineering, 2018, 126, 153-161.	2.2	2
29	Structural considerations for functional anti-EGFR Ã— anti-CD3 bispecific diabodies in light of domain order and binding affinity. Oncotarget, 2018, 9, 13884-13893.	1.8	12
30	Engineering the hinge region of human IgG1 Fc-fused bispecific antibodies to improve fragmentation resistance. Scientific Reports, 2018, 8, 17253.	3.3	15
31	Convenient and Universal Fabrication Method for Antibodyâ€“Enzyme Complexes as Sensing Elements Using the SpyCatcher/SpyTag System. Analytical Chemistry, 2018, 90, 14500-14506.	6.5	22
32	Compact Seahorseâ€Shaped TÂCellâ€“Activating Antibody for Cancer Therapy. Advanced Therapeutics, 2018, 1, 1700031.	3.2	4
33	Esterification of PQQ Enhances Blood-Brain Barrier Permeability and Inhibitory Activity against Amyloidogenic Protein Fibril Formation. ACS Chemical Neuroscience, 2018, 9, 2898-2903.	3.5	10
34	Comprehensive study of domain rearrangements of single-chain bispecific antibodies to determine the best combination of configurations and microbial host cells. MAbs, 2018, 10, 854-863.	5.2	11
35	Chemo-enzymatic Total Syntheses of Jorunnamycin A, Saframycin A, and N-Fmoc Saframycin Y3. Journal of the American Chemical Society, 2018, 140, 10705-10709.	13.7	24
36	A semi high-throughput method for screening small bispecific antibodies with high cytotoxicity. Scientific Reports, 2017, 7, 2862.	3.3	17

#	Article	IF	Citations
37	Antiâ€<scp>EGFR</scp> scFv tetramer (tetrabody) with a stable monodisperse structure, strong anticancer effect, and a long in vivo halfâ€life. FEBS Open Bio, 2016, 6, 594-602.	2.3	10
38	OUP accepted manuscript. Protein Engineering, Design and Selection, 2016, 30, 15-21.	2.1	7
39	Rearranging the domain order of a diabody-based IgG-like bispecific antibody enhances its antitumor activity and improves its degradation resistance and pharmacokinetics. MAbs, 2014, 6, 1243-1254.	5.2	20
40	Trehalose suppresses antibody aggregation during the culture of Chinese hamster ovary cells. Journal of Bioscience and Bioengineering, 2014, 117, 632-638.	2.2	20
41	Glycosylation analysis of an aggregated antibody produced by Chinese hamster ovary cells in bioreactor culture. Journal of Bioscience and Bioengineering, 2014, 117, 639-644.	2.2	25
42	Multimerization of antiâ€(epidermal growth factor receptor) IgG fragments induces an antitumor effect: the case for humanized 528 scFv multimers. FEBS Journal, 2013, 280, 4816-4826.	4.7	11
43	Development of an affinity-matured humanized anti-epidermal growth factor receptor antibody for cancer immunotherapy. Protein Engineering, Design and Selection, 2013, 26, 113-122.	2.1	10
44	Domain order of a bispecific diabody dramatically enhances its antitumor activity beyond structural format conversion: the case of the hEx3 diabody. Protein Engineering, Design and Selection, 2013, 26, 359-367.	2.1	34
45	A nanocluster design for the construction of artificial cellulosomes. Catalysis Science and Technology, 2012, 2, 499.	4.1	22
46	1C1448 Protein engineering for site-specific bioconjugation chemistry : Construction of multiple functional low-molecular antibodies(Proteins: Measurement, Analysis, Engineering,Oral) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 382 Td (P S23.	0.1	0
47	Construction and humanization of a functional bispecific EGFRâ€ƒÃ—â€ƒCD16 diabody using a refolding system. FEBS Journal, 2012, 279, 223-233.	4.7	31
48	In vitro and in vivo antitumor effects of recombinant bispecific antibodies based on humanized anti-EGFR antibody. Oncology Reports, 2011, 26, 949-55.	2.6	14
49	Cytotoxic Enhancement of a Bispecific Diabody by Format Conversion to Tandem Single-chain Variable Fragment (taFv). Journal of Biological Chemistry, 2011, 286, 1812-1818.	3.4	26
50	Application of the Fc fusion format to generate tagâ€free biâ€specific diabodies. FEBS Journal, 2010, 277, 477-487.	4.7	27
51	Highly Enhanced Cytotoxicity of a Dimeric Bispecific Diabody, the hEx3 Tetrabody. Journal of Biological Chemistry, 2010, 285, 20844-20849.	3.4	23
52	Thermodynamic Consequences of Mutations in Vernier Zone Residues of a Humanized Anti-human Epidermal Growth Factor Receptor Murine Antibody, 528. Journal of Biological Chemistry, 2008, 283, 1156-1166.	3.4	86
53	Preferential heterodimerization of a bispecific diabody based on a humanized anti-EGFR antibody 528. Protein Engineering, Design and Selection, 2008, 21, 597-603.	2.1	11
54	Diabody-based Recombinant Formats of Humanized IgG-like Bispecific Antibody With Effective Retargeting of Lymphocytes to Tumor Cells. Journal of Immunotherapy, 2008, 31, 752-761.	2.4	29

#	Article	IF	Citations
55	Highly Effective Recombinant Format of a Humanized IgG-like Bispecific Antibody for Cancer Immunotherapy with Retargeting of Lymphocytes to Tumor Cells. Journal of Biological Chemistry, 2007, 282, 27659-27665.	3.4	51
56	Humanization of the Bispecific Epidermal Growth Factor Receptor Ã— CD3 Diabody and Its Efficacy as a Potential Clinical Reagent. Clinical Cancer Research, 2006, 12, 4036-4042.	7.0	62
57	Tumor-directed lymphocyte-activating cytokines: refolding-based preparation of recombinant human interleukin-12 and an antibody variable domain-fused protein by additive-introduced stepwise dialysis. Biochemical and Biophysical Research Communications, 2005, 328, 98-105.	2.1	29
58	A highly effective and stable bispecific diabody for cancer immunotherapy: cure of xenografted tumors by bispecific diabody and T-LAK cells. Cancer Immunology, Immunotherapy, 2004, 53, 497-509.	4.2	35
59	Selected IL-21R Expression and Apoptosis Induction by IL-21 in Follicular Lymphoma.. Blood, 2004, 104, 2284-2284.	1.4	1
60	Efficient Construction of a Diabody Using a Refolding System: Anti- Carcinoembryonic Antigen Recombinant Antibody Fragment. Journal of Biochemistry, 2002, 132, 903-909.	1.7	21
61	Selection of human antibody fragments on the basis of stabilization of the variable domain in the presence of target antigens. Biochemical and Biophysical Research Communications, 2002, 295, 31-36.	2.1	7
62	Construction of a diabody (small recombinant bispecific antibody) using a refolding system. Protein Engineering, Design and Selection, 2000, 13, 583-588.	2.1	28
63	Functional Fv fragment of an antibody specific for CD28: Fv-mediated co-stimulation of T cells. FEBS Letters, 2000, 476, 266-271.	2.8	7